Beam Therapeutics (BEAM) Free Cash Flow (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Free Cash Flow data on file, last reported at -$130.7 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 22.25% year-over-year to -$130.7 million in Q1 2026; TTM through Mar 2026 was -$370.2 million, a 4.91% decrease from a year earlier, with the FY2025 full-year figure at -$346.4 million, changed 0.49% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$130.7 million, down from -$81.4 million in the prior quarter.
• Over the last five years, Free Cash Flow for BEAM reached as high as $203.2 million in Q1 2022 and fell as low as -$130.7 million in Q1 2026.
• Historically, Free Cash Flow has averaged -$59.0 million across 5 years, with a median of -$84.2 million in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 624.17% in 2022 and fell as far as 3733.5% in 2022.
• Year by year, Free Cash Flow stood at -$77.5 million in 2022, then surged by 311.5% to $163.8 million in 2023, then plunged by 146.85% to -$76.7 million in 2024, then fell by 6.11% to -$81.4 million in 2025, then plunged by 60.55% to -$130.7 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$130.7 million in Q1 2026, -$81.4 million in Q4 2025, and -$78.4 million in Q3 2025.